Autolus Therapeutics operates as a clinical-stage biopharmaceutical leader focusing on advanced T-cell therapies, competing directly against other prominent cell therapy and oncology innovators such as Gilead subsidiary Kite Pharma, Novartis, Bristol Myers Squibb, and specialized biotechnology firms developing engineered immunotherapies for cancer and autoimmune conditions.